• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Intrahost modeling of artemisinin resistance in Plasmodium falciparum.疟原虫青蒿素耐药性的宿主内建模。
Proc Natl Acad Sci U S A. 2011 Jan 4;108(1):397-402. doi: 10.1073/pnas.1006113108. Epub 2010 Dec 20.
2
Artemisinin resistance in Plasmodium falciparum malaria.恶性疟原虫疟疾中的青蒿素耐药性。
N Engl J Med. 2009 Jul 30;361(5):455-67. doi: 10.1056/NEJMoa0808859.
3
Effect of high-dose or split-dose artesunate on parasite clearance in artemisinin-resistant falciparum malaria.青蒿琥酯高剂量或分剂量给药对耐青蒿素恶性疟原虫疟疾寄生虫清除的影响。
Clin Infect Dis. 2013 Mar;56(5):e48-58. doi: 10.1093/cid/cis958. Epub 2012 Nov 21.
4
Pharmacokinetics and pharmacodynamics of oral artesunate monotherapy in patients with uncomplicated Plasmodium falciparum malaria in western Cambodia.柬埔寨西部无并发症恶性疟原虫感染患者口服青蒿琥酯单药疗法的药代动力学和药效学。
Antimicrob Agents Chemother. 2012 Nov;56(11):5484-93. doi: 10.1128/AAC.00044-12. Epub 2012 Aug 6.
5
Artemisinin-resistant Plasmodium falciparum in Pursat province, western Cambodia: a parasite clearance rate study.柬埔寨西部磅士卑省的青蒿素耐药疟原虫:寄生虫清除率研究。
Lancet Infect Dis. 2012 Nov;12(11):851-8. doi: 10.1016/S1473-3099(12)70181-0. Epub 2012 Aug 30.
6
Reduced susceptibility of Plasmodium falciparum to artesunate in southern Myanmar.缅甸南部恶性疟原虫对青蒿琥酯的敏感性降低。
PLoS One. 2013;8(3):e57689. doi: 10.1371/journal.pone.0057689. Epub 2013 Mar 8.
7
Laboratory detection of artemisinin-resistant Plasmodium falciparum.青蒿素耐药性恶性疟原虫的实验室检测
Antimicrob Agents Chemother. 2014 Jun;58(6):3157-61. doi: 10.1128/AAC.01924-13. Epub 2014 Mar 24.
8
Defining the in vivo phenotype of artemisinin-resistant falciparum malaria: a modelling approach.界定青蒿素耐药恶性疟原虫的体内表型:一种建模方法。
PLoS Med. 2015 Apr 28;12(4):e1001823. doi: 10.1371/journal.pmed.1001823. eCollection 2015 Apr.
9
Population pharmacokinetic and pharmacodynamic properties of artesunate in patients with artemisinin sensitive and resistant infections in Southern Myanmar.缅甸南部青蒿素敏感和耐药感染患者青蒿琥酯的群体药代动力学和药效学特性。
Malar J. 2018 Mar 23;17(1):126. doi: 10.1186/s12936-018-2278-5.
10
Artemisinin resistance containment project in Thailand. II: Responses to mefloquine-artesunate combination therapy among falciparum malaria patients in provinces bordering Cambodia.泰国的青蒿素耐药遏制项目。二:柬埔寨边境省份间恶性疟疾病例对青蒿琥酯-甲氟喹联合疗法的反应。
Malar J. 2012 Aug 28;11:300. doi: 10.1186/1475-2875-11-300.

引用本文的文献

1
Evaluation of a Bayesian hierarchical pharmacokinetic-pharmacodynamic model for predicting parasitological outcomes in Phase 2 studies of new antimalarial drugs.评估一种贝叶斯分层药代动力学-药效学模型,用于预测新型抗疟药物 2 期研究中的寄生虫学结局。
Antimicrob Agents Chemother. 2024 Sep 4;68(9):e0086324. doi: 10.1128/aac.00863-24. Epub 2024 Aug 13.
2
Photoaffinity probe-based antimalarial target identification of artemisinin in the intraerythrocytic developmental cycle of .基于光亲和探针的青蒿素在疟原虫红细胞内发育周期中的抗疟靶点鉴定 。 你提供的原文似乎不完整,句末的“of.”后面缺少具体内容。
Imeta. 2024 Feb 19;3(2):e176. doi: 10.1002/imt2.176. eCollection 2024 Apr.
3
Characterisation of Plasmodium vivax lactate dehydrogenase dynamics in P. vivax infections.评价间日疟原虫乳酸脱氢酶动力学在间日疟原虫感染中的作用。
Commun Biol. 2024 Mar 22;7(1):355. doi: 10.1038/s42003-024-05956-6.
4
The Kelch13 compartment contains highly divergent vesicle trafficking proteins in malaria parasites.Kelch13 隔室中含有疟原虫中高度分化的囊泡运输蛋白。
PLoS Pathog. 2023 Dec 1;19(12):e1011814. doi: 10.1371/journal.ppat.1011814. eCollection 2023 Dec.
5
An artesunate pharmacometric model to explain therapeutic responses in falciparum malaria.青蒿琥酯药代动力学模型解释恶性疟原虫疟疾的治疗反应。
J Antimicrob Chemother. 2023 Sep 5;78(9):2192-2202. doi: 10.1093/jac/dkad219.
6
Artemisinin resistance and malaria elimination: Where are we now?青蒿素耐药性与疟疾消除:我们目前处于什么状况?
Front Pharmacol. 2022 Sep 23;13:876282. doi: 10.3389/fphar.2022.876282. eCollection 2022.
7
Daily rhythms of both host and parasite affect antimalarial drug efficacy.宿主和寄生虫的日常节律都会影响抗疟药物的疗效。
Evol Med Public Health. 2021 Apr 26;9(1):208-219. doi: 10.1093/emph/eoab013. eCollection 2021.
8
Plasmodium falciparum resistance to ACTs: Emergence, mechanisms, and outlook.恶性疟原虫对青蒿素类复方药物的抗药性:出现、机制和展望。
Int J Parasitol Drugs Drug Resist. 2021 Aug;16:102-118. doi: 10.1016/j.ijpddr.2021.05.007. Epub 2021 May 26.
9
Artificial intelligence as a fundamental tool in management of infectious diseases and its current implementation in COVID-19 pandemic.人工智能作为传染病管理的基本工具及其在 COVID-19 大流行中的当前应用。
Environ Sci Pollut Res Int. 2021 Aug;28(30):40515-40532. doi: 10.1007/s11356-021-13823-8. Epub 2021 May 25.
10
Development and Validation of an Decision Tool To Guide Optimization of Intravenous Artesunate Dosing Regimens for Severe Falciparum Malaria Patients.开发并验证一个决策工具,以指导优化重症恶性疟患者的静脉注射青蒿琥酯给药方案。
Antimicrob Agents Chemother. 2021 May 18;65(6). doi: 10.1128/AAC.02346-20.

本文引用的文献

1
Artemisinin‐induced dormancy in plasmodium falciparum: duration, recovery rates, and implications in treatment failure.青蒿素诱导恶性疟原虫休眠:持续时间、恢复率及其对治疗失败的影响
J Infect Dis. 2010 Nov 1;202(9):1362-8. doi: 10.1086/656476.
2
High heritability of malaria parasite clearance rate indicates a genetic basis for artemisinin resistance in western Cambodia.高疟原虫清除率的遗传力表明柬埔寨西部青蒿素耐药性存在遗传基础。
J Infect Dis. 2010 May 1;201(9):1326-30. doi: 10.1086/651562.
3
Increased tolerance to artemisinin in Plasmodium falciparum is mediated by a quiescence mechanism.疟原虫对青蒿素的耐受性增加是由休眠机制介导的。
Antimicrob Agents Chemother. 2010 May;54(5):1872-7. doi: 10.1128/AAC.01636-09. Epub 2010 Feb 16.
4
Artemisinin resistance in Plasmodium falciparum malaria.恶性疟原虫疟疾中的青蒿素耐药性。
N Engl J Med. 2009 Jul 30;361(5):455-67. doi: 10.1056/NEJMoa0808859.
5
Pharmacokinetic determinants of the window of selection for antimalarial drug resistance.抗疟药物耐药性选择窗的药代动力学决定因素。
Antimicrob Agents Chemother. 2008 May;52(5):1589-96. doi: 10.1128/AAC.00903-07. Epub 2008 Feb 25.
6
Estimation of the total parasite biomass in acute falciparum malaria from plasma PfHRP2.通过血浆PfHRP2估计急性恶性疟原虫疟疾中的总寄生虫生物量。
PLoS Med. 2005 Aug;2(8):e204. doi: 10.1371/journal.pmed.0020204. Epub 2005 Aug 23.
7
Stage-dependent production and release of histidine-rich protein 2 by Plasmodium falciparum.恶性疟原虫富含组氨酸蛋白2的阶段依赖性产生与释放
Trans R Soc Trop Med Hyg. 2005 Jul;99(7):517-24. doi: 10.1016/j.trstmh.2004.11.014.
8
The assessment of antimalarial drug efficacy.抗疟药物疗效的评估。
Trends Parasitol. 2002 Oct;18(10):458-64. doi: 10.1016/s1471-4922(02)02373-5.
9
Population dynamics of untreated Plasmodium falciparum malaria within the adult human host during the expansion phase of the infection.感染扩展阶段成年人类宿主内未治疗的恶性疟原虫疟疾的种群动态。
Parasitology. 2002 Mar;124(Pt 3):247-63. doi: 10.1017/s0031182001001202.
10
Mathematical modelling of malaria chemotherapy: combining artesunate and mefloquine.疟疾化疗的数学建模:青蒿琥酯与甲氟喹联用
Parasitology. 2002 Jan;124(Pt 1):9-15. doi: 10.1017/s0031182001008952.

疟原虫青蒿素耐药性的宿主内建模。

Intrahost modeling of artemisinin resistance in Plasmodium falciparum.

机构信息

Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Rajthevee, Bangkok 10400, Thailand.

出版信息

Proc Natl Acad Sci U S A. 2011 Jan 4;108(1):397-402. doi: 10.1073/pnas.1006113108. Epub 2010 Dec 20.

DOI:10.1073/pnas.1006113108
PMID:21173254
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3017155/
Abstract

Artemisinin-resistant Plasmodium falciparum malaria has emerged in western Cambodia. Resistance is characterized by prolonged in vivo parasite clearance times (PCTs) following artesunate treatment. The biological basis is unclear. The hypothesis that delayed parasite clearance results from a stage-specific reduction in artemisinin sensitivity of the circulating young asexual parasite ring stages was examined. A mathematical model was developed, describing the intrahost parasite stage-specific pharmacokinetic-pharmacodynamic relationships. Model parameters were estimated using detailed pharmacokinetic and parasite clearance data from 39 patients with uncomplicated falciparum malaria treated with artesunate from Pailin (western Cambodia) where artemisinin resistance was evident and 40 patients from Wang Pha (northwestern Thailand) where efficacy was preserved. The mathematical model reproduced the observed parasite clearance for each patient with an accurate goodness of fit (rmsd: 0.03-0.67 in log(10) scale). The parameter sets that provided the best fits with the observed in vivo data consist of a highly conserved concentration-effect relationship for the trophozoite and schizont parasite stages, but a variable relationship for the ring stages. The model-derived assessment suggests that the efficacy of artesunate on ring stage parasites is reduced significantly in Pailin. This result supports the hypothesis that artemisinin resistance mainly reflects reduced ring-stage susceptibility and predicts that doubling the frequency of dosing will accelerate clearance of artemisinin-resistant parasites.

摘要

在柬埔寨西部已出现青蒿素耐药恶性疟。耐药的特征是青蒿琥酯治疗后寄生虫清除时间(PCT)延长。其生物学基础尚不清楚。我们研究了这样一种假说,即寄生虫清除延迟是由于循环中的年轻无性环状滋养体阶段对青蒿素的敏感性特定阶段降低所致。我们开发了一个数学模型,描述了宿主内寄生虫阶段特异性药代动力学-药效动力学关系。使用来自柬埔寨西部柏威夏(青蒿素耐药明显)和泰国西北部旺帕(疗效保存)的 39 例青蒿琥酯治疗的无并发症恶性疟患者的详细药代动力学和寄生虫清除数据,对模型参数进行了估计。该数学模型准确地再现了每个患者的寄生虫清除情况(拟合优度 rmsd:在对数尺度上为 0.03-0.67)。提供与观察到的体内数据最佳拟合的参数集包括对滋养体和裂殖体寄生虫阶段的高度保守的浓度-效应关系,但环状阶段的关系是可变的。模型推导的评估表明,青蒿琥酯对环状阶段寄生虫的疗效在柏威夏显著降低。这一结果支持了青蒿素耐药主要反映环状阶段易感性降低的假说,并预测增加青蒿琥酯给药频率将加速清除青蒿素耐药寄生虫。